Clinical Trials Logo

NSCLC Stage IV clinical trials

View clinical trials related to NSCLC Stage IV.

Filter by:

NCT ID: NCT03827850 Terminated - Lung Cancer Clinical Trials

FGFR Inhibitor in FGFR Dysregulated Cancer

FIND
Start date: March 25, 2019
Phase: Phase 2
Study type: Interventional

In the FIND trial, Non Small Cell Lung Carcinoma (NSCLC) patients with Fibroblast Growth Factor Receptor (FGFR) genetic alteration will be treated with the selective FGFR1-4 inhibitor erdafitinib. Archival samples, fresh frozen tumor samples and blood for circulating tumor DNA (ctDNA) will be collected before treatment. Patients will be treated until disease progression or unacceptable toxicity. In case of progression, fresh frozen tumor biopsies and ctDNA analyses will be performed to assess resistance mechanisms. The primary objective of the trial is to analyze the efficacy of erdafitinib in NSCLC patients with FGFR genetic alterations. NSCLC patient number will be based on a statistical hypothesis aiming at increasing the response rate comparing to chemotherapy/immunotherapy after standard treatment.

NCT ID: NCT03808662 Active, not recruiting - Clinical trials for Non Small Cell Lung Cancer

Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung

Start date: January 16, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is determine if receiving stereotactic body radiation(SBRT) when participants' metastatic tumors have just begun to grow increase the length of time before disease gets worse

NCT ID: NCT03805841 Terminated - NSCLC Stage IIIB Clinical Trials

Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions

RAIN
Start date: March 13, 2019
Phase: Phase 2
Study type: Interventional

Open-label, Phase 2, single treatment arm, 3 cohorts

NCT ID: NCT03777124 Not yet recruiting - Chemotherapy Effect Clinical Trials

Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer

Start date: February 2019
Phase: Phase 2
Study type: Interventional

This is a randomized, open-label, multi-center, phase II trial to evaluate the efficacy and safety of SHR-1210 plus apatinib mesylate versus Pemetrexed and Carboplatin in Subjects with KRAS mutant stage IV non-squamous Non-small Cell Lung Cancer

NCT ID: NCT03713944 Terminated - NSCLC Stage IV Clinical Trials

Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer

Start date: November 15, 2018
Phase: Phase 2
Study type: Interventional

This is a multicenter single arm phase II clinical trial. All eligible patients will receive: Carboplatin (AUC 5) i.v. day 1 plus pemetrexed (500 mg/m2) i.v. day 1 plus atezolizumab 1200 mg i.v. day 1 plus bevacizumab 15 mg/kg i.v. day 1 every 3 weeks for up to 4 cycles. Patients with non-PD after 4 cycles will be permitted to continue with maintenance therapy with pemetrexed plus atezolizumab plus bevacizumab every 3 weeks until the time of disease progression or intolerable toxicities.

NCT ID: NCT03705403 Active, not recruiting - NSCLC Stage IV Clinical Trials

IMMUNOtherapy and Stereotactic ABlative Radiotherapy (IMMUNOSABR) a Phase II Study

IMMUNOSABR2
Start date: April 4, 2019
Phase: Phase 2
Study type: Interventional

This will be a phase II trial testing if the combination of stereotactic ablative body radiotherapy (SABR) and L19-IL2 improve the progression-free survival in patients with limited metastatic non-small cell lung cancer (NSCLC). The trial consists of one cohort with two arms; C-arm and an E-arm. Patients with oligometastatic disease will receive SABR to minimal 1 and max all metastatic sites (max 5 sites irradiated) and patients with diffuse metastatic lesions (6 to max 10) will receive radiotherapy to max 5 sites. In the experimental arm, immunotherapy will be given after irradiation.

NCT ID: NCT03647956 Recruiting - NSCLC Stage IV Clinical Trials

Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors

Start date: October 1, 2018
Phase: Phase 2
Study type: Interventional

This project will recruit 40 EGFR-mutant metastatic non-small cell lung cancer patients who failed any EGFR tyrosine kinase inhibitors. All recruited patients will receive 1200mg Azetolizumab administered over 60 minutes (1st cycle) and 30 minutes (2nd cycle onwards) intravenously, as well as 7.5mg/kg bevacizumab administered over 90 minutes (1st cycle), 60 minutes (2nd cycle) and 30 minutes (3rd cycle onwards) for every 3 weeks, until radiographically documented disease progression, unacceptable toxicity as judged by investigators or patient withdrawal. The primary objective is to assess the progression-free survival of this treatment population, and to identify potential genomic and immunologic biomarkers for treatment response. Objective response rate (ORR) will be the primary efficacy endpoint.

NCT ID: NCT03620669 Active, not recruiting - NSCLC Stage IV Clinical Trials

1st Line Durvalumab in PS 2 NSCLC Patients

Start date: December 4, 2018
Phase: Phase 2
Study type: Interventional

The aim of the trial is to assess efficacy and safety of the treatment with durvalumab in PS 2 patients with treatment-naïve, locally advanced or metastatic, PD-L1 positive NSCLC who are considered unsuitable for combination platinum-containing therapy.

NCT ID: NCT03594682 Not yet recruiting - NSCLC Stage IV Clinical Trials

Optimizing the Therapeutic Dose of Apatinib Mesylate Tablets in Patients With Lung Cancer by Dose Titration:A Real World Exploratory Study

Start date: August 2018
Phase: N/A
Study type: Interventional

The purpose of the study is to evaluate the safety and efficacy of two different administration methods of apatinib in NSCLC patients.

NCT ID: NCT03564197 Recruiting - NSCLC Stage IV Clinical Trials

18F-PD-L1 PET/CT in Nivolumab Treated Patients With NSCLC

Start date: October 25, 2018
Phase: N/A
Study type: Interventional

A multicenter single arm biomarker exploration and validation study. Eighty patients with NSCLC that are eligible for first line chemo-immunotherapy, first line nivolumab/ipilimumab or 2nd line and beyond PD-(L)1 immunotherapy monotherapy according to EMA label and national guidelines will be enrolled in this trial. All subjects will undergo a whole body 18F-PD-L1 PET/CT scan before start of nivolumab containing treatment. Patients will continue treatment until disease progression, withdrawal of patient consent or unacceptable toxicity.